Magenta reports Phase II engraftment data for MGTA-456

Magenta Therapeutics Inc. (Cambridge, Mass.) reported data from an open-label, U.S. Phase II trial showing MGTA-456 as a stand-alone

Read the full 195 word article

User Sign In